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Abstract
Access to medicine remains poor and inequitable in many low- and middle-income countries (LMICs). This is a complex and 
multi-dimensional issue calling for holistic solutions. Studies in this area focus on singular disciplines, highlighting one or two main 
issues; this paper seeks to consider this issue from a multi-disciplinary perspective. It first enumerates the supply chain bottlenecks 
which lead to poor access to medicine. Since access is dependent on a host of factors, it is critical to understand each of these in the 
context of LMICs. Secondly, the paper proposes interventions to improve access by focusing on availability, affordability, quality and 
obtainability of medicine. These interventions are categorised into broader areas of focus to help stakeholders understand their role 
and responsibilities across the supply chain functions. Finally, the paper establishes a rationale for each intervention, matching it to 
a WHO Building Block and the corresponding supply chain management function. The resulting map will allow stakeholders to envi-
sion policies that will contribute to comprehensive solutions that strengthen the public health supply chains in LMICs.
LMIC: Low- and Middle-Income Countries; WHO: World Health 
Organisation; OECD:Organisation for Economic Co-operation and 
Development; NCD: Non-Communicable Diseases; IFPMA: Interna-
tional Federation of Pharmaceutical Manufacturers and Associa-
tions; MDG: Millennium Development Goals; GFTAM:Global Fund 
to Fight AIDS, Tuberculosis and Malaria; AMREF: The African Medi-
cal and Research Foundation; SCM: Supply Chain Management; R & 
D: Research and Development; CEWG: Consultative Expert Work-
ing Group; GRO: Grassroots Organisations.
Abbreviations
Keywords: Access to Medicine; Supply Chain; Interventions; WHO Building Blocks
The growth in development aid has slowed since 2011 by near-
ly 3 per cent due to donor fatigue and this is a worrying factor for 
LMICs who rely on donor funds to improve healthcare facilities [2]. 
Government health expenditure, as a percentage of GDP, has been 
declining in LMICs, leaving professionals to do more on fewer re-
sources [3]. The declining investment and expenditure have driven 
the poor away from the public health system. The credibility and 
effectiveness of health systems are linked is reflected on the pa-
tient’s ability to obtain the right medication, at the right time, and 
at the right cost. A medical diagnosis is effective only when it is 
supported by accessibility to the required medication. This be-
comes a benchmark for the quality of healthcare and can act as an 
impetus for improving universal healthcare coverage. Most low- and middle-income countries lag behind in providing 
healthcare to their populace, in spite of the Health for All by 2000 
initiative [1]. The difficulties in providing good quality health-
care have been a cause of concern, as maintaining the quality of 
medicine and guaranteeing the availability of health commodities 
at affordable prices depends on a host of factors that need to be 
synchronised and integrated for the system to be efficient. In most 
of these countries, the existing health system (both public and pri-
vate) is far from being satisfactory, the availability of basic medi-
cine is inadequate, and it is expensive. Improving access to medi-
cine is dependent upon a host of factors and the involvement of a 
variety of participants.
Introduction
In 2015, the UN agreed that Sustainable Development Goals will 
include targets such as the elimination of major disease epidemics 
and the reduction of the burden of childhood obesity. The progress 
in global health is not inevitable and requires consistent efforts by 
countries, donors, policymakers, supply chain participants, etc. In 
2017, the improvements in global mortality rates were less pro-
nounced than in the previous decade, and non-communicable 
diseases (NCDs), for example, accounted for 73.4% of deaths, an 
increase of 22.7% since 2007 [4]. This was attributed to changing 
diets, urbanisation, and sedentary lifestyles. Moreover, inappropri-
ate and overuse of medication coupled with wastage of resources 
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In addition, new public health challenges are putting further 
pressure on already strained health systems and contributing to a 
high volume of out-of-pocket expenses in LMICs. These challenges 
include supply chain impediments coupled with legislative and 
economic transitions taking place in different countries. The vari-
ous stakeholders including the scientific research community, local 
governments, public health and regulatory agencies, overseas de-
velopment agencies, philanthropists, multi-lateral agencies and the 
non-profit sector’s specific duties will contribute to the improve-
ment of healthcare coverage.
created a gap between the demand and supply that will ultimately 
lead to a loss of social protection for the poor [5].
In many respects, the cornerstones of public health growth 
are the pharmaceutical companies who should aim to ensure that 
medicine is available and accessible, irrespective of socio-economic 
considerations. These companies have the power to improve sup-
ply chains and save lives by providing better access to medicine 
at affordable prices. Through purposeful collaborations, the said 
companies can respond to the changing disease patterns, introduce 
new products and technologies, and promote sustainable, long-
term access to medicine. 
Emerging economies accounted for 23% of global spending on 
pharmaceuticals in 2015 and they are expected to account for 25% 
by 2020 [6]. Since exact predictions of diseases and outbreaks are 
not always possible, a collaborative approach between the public 
and private sector to develop, support and implement innovative 
practice is of utmost importance. The ideal solution to these chal-
lenges would be to introduce free provision of medicine to patients 
with low costs for governments. This would help to improve health 
benefits and decrease out-of-pocket expenditures. However, in 
spite of the attempts to support this approach, not much progress 
has been witnessed in LMICs [7].
Since the adoption of the Millennium Development Goals (MDG) 
in 2000 and the establishment of the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (GFTAM) in 2002, there has been an in-
crease in financial donations from multilateral and bilateral donors 
to LMICs [8,9], resulting in an exponential increase in the procure-
ment of medical products. But the success of health programmes is 
not only dependent on the availability of funds to finance the pro-
curement of medicine; if these medicines are inaccessible to the 
patients who require them, suffering and premature mortality will 
persist. Issues with access to medicine remain one of the leading 
causes of preventable deaths and poor health outcomes in LMICs.
Literature Review
Supply chains and the corresponding management
Van Wassenhove [11], outlines three types of flows supported 
by a supply chain that require careful design and close coordina-
tion. Those include material flows, the physical product flows from 
suppliers to customers, including reverse flows for product returns, 
servicing, and recycling; information flows, such as order transmis-
sion and order tracking, which coordinate the material flows; and 
financial flows–credit terms, payment schedules, and consignment 
arrangements. Closely related to ‘supply chain’ is ‘supply chain 
management’ (SCM). To some, SCM is the coordination of the sup-
ply chain activities [12]. Others provide similar definitions but re-
fer to ‘business functions’ rather than ‘activities,’ reflecting their 
view of the supply chain as a network of entities [13].
Health systems
The World Health Organization (WHO) defines a health system 
as ‘all the activities whose primary purpose is to promote, restore 
or maintain health’ [14]. The WHO 2007 framework for health sys-
tems is widely recognised, and its broad approach is the most suit-
able for identifying the range of issues that might affect the avail-
ability of medicine. It consists of six interconnected building blocks, 
required for an effective health system, namely, service delivery, 
health workforce, information, medical products, vaccines and 
technology, financing, and leadership and governance. According to 
Shakarishvili et al. [15], this approach is ‘a useful means for locat-
ing, describing, and classifying health system constraints, for iden-
tifying where and why investments are needed, what will happen 
as a result, and by what means the change can be monitored’ [15].
Building on the literature review, this paper examines and as-
sesses the strategies for improving the accessibility of medicine 
LMICs. The paper highlights supply chain challenges throughout 
the process and the resultant effect on health systems. This paper 
recommends areas for holistic improvement. The paper will help to 
disseminate information and shorten the learning curve of all the 
stakeholders involved in trying to improve the health outcomes of 
any developing nation. The paper is structured as follows: Section 
2 discusses the supply chain bottlenecks in achieving better medi-
cine accessibility; Section 3 highlights interventions to increase 
healthcare coverage through improved access to medicine; Section 
4 matches the interventions to WHO building blocks and supply 
chain management; and Section 5 concludes the paper
Public health supply chains carry the responsibility of improv-
ing the health outcomes by addressing inaccessibility, which can 
put an additional strain on the already struggling complex public 
health supply chain. Despite increased donor funding and an ar-
ray of new products (including vaccines and essential medicine), 
there are factors that continue to restrict access to health products. 
Namely, the capacity of a country’s supply chain to select, forecast, 
procure, and deliver health supplies is a major hinderance [10]. 
There is an urgent need for more research into public health supply 
chains in LMICs if any improvement in the access to medicine is to 
be made. 
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Supply chain bottlenecks in achieving better medicine acces-
sibility
The methods of procurement and distribution of medicine can 
vary across countries. However, supply chain issues and disruptions 
can interrupt the availability of medicine at the lower echelons of 
the population. Procurement delays can hamper the patients’ con-
fidence in public health systems and defeat the basic purpose of 
public health supply chain. Delays can emerge due to supplier mis-
management, delayed tendering, customs issues, poor specifica-
tions and many more. Moreover, each country has its unique set of 
challenges which cannot be solved through generalised solutions. 
Therefore, understanding contextualised factors and avoiding non-
customised approaches is a step towards better health outcomes. 
The following table highlights the key supply chain challenges 
and the solutions required to overcome them in an LMIC context. 





•	 Poor selection of essential medicine
•	 Lack of standard practice
•	 Lack of transparency
•	 Low human capacity to carry on this function
•	 Proper understanding of the Essential Medicine List
•	 Linking requirements to disease pattern of the country 
through proper data collection and feedback system
Quantification
•	 Inadequate and less-reliable data on consumption
•	 Poor quantification and forecasting skills
•	 Evidence-based decisions
•	 Ability to forecast built on need and patient demand
Procurement •	 Unclear procedures
•	 Procedural delays due to poor quantification
•	 Use of low/outdated technology
•	 Supplier uncertainty
•	 Matching of procurement to the Essential Medicine List
•	 Use of technology to reduce lead times and expedite pro-
curement cycle
•	 Better supplier selection and management
Quality of the 
medicines
•	 Counterfeit drugs crowding the public health sys-
tems
•	 Treatment failures extending illness, adverse reac-
tions, disability and death (IFPMA)
•	 Detection is also difficult as the supply chain uti-
lizes complex international trade routes, within 
a system where police, customs, and drug regula-
tors are not unified (WHO)
•	 Strict quality checks and adherence to criteria
•	 Blacklisting of suppliers for substandard/spurious medi-
cine
•	 Sample testing at delivery points and along the supply 
chain by independent accredited laboratories.
•	 Use of modern technology
Inventory 
management
•	 Mismatch between demand and supply
•	 Inadequate methods of inventory control leading 
to overstocking/understocking
•	 Lack of human capacity
•	 Inventory decisions based on consumption data
•	 Real-time inventory data shared across the public health 
supply chains for better replenishment and distribution 
strategies.
Warehousing
•	 Poor conditions of storage facilities
•	 Lack of adequate infrastructure (temperature con-
trol)
•	 Low utilisation of technology
•	 Reduced security and human capacity
•	 Adoption of a warehouse management system
•	 Modern infrastructure for fast order processing, such as 
racking and mechanical handling equipment (MHE)
•	 Well-trained and skilled staff for warehouse operations; 
storage and security.
Distribution •	 Low availability of good quality public transport 
and very expensive private fleet 
•	 Low frequency of distribution to lower tiers and 
rural areas
•	 Last-mile delivery failure due to inaccessible loca-
tions and transportation constraints
•	 Poor coordination between the central warehous-
es and health facilities
•	 Using modern fleet management technology to improve 
distribution
•	 Embracing GPS enabled last mile delivery for better health 
outcomes
•	 Outsourcing, depending on the health commodities and 




•	 Low human capacity
•	 Lack of clear procedures
•	 Poor vendor management practice
•	 Capacity development through workforce engagement 
and motivation
•	 Performance management tools to instil better feedback 
and structure
•	 Improved relationship management supporting long-
term alliances and support
Capacity planning and development is crucial throughout the 
supply chain functions [16]. LMICs often face skill-gaps which 
contributes to the fragmentation and inefficiency of public health 
systems. There continues to be a dire need for training and capac-
ity development of existing staff [17]. The employment of procure-
ment staff without the right qualifications and training further 
jeopardises the procurement system. Employees become vulner-
able to audit and vigilance issues, leading to defensive office pro-
cedures. Furthermore, the distribution of medicine, in terms of 
last-mile delivery, can pose various challenges due to insufficient 
infrastructure and lack of legislative support.
Table 1: Supply chain challenges and requirements to be met to improve the availability of medicine in LMICs.
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problems of governance, poor political support, ineffective leader-
ship and constant reshuffling of key positions when trying to push 
for reforms could continue to hamper the process.
Interventions to increase healthcare coverage through im-
proved access to medicine 
The various supply chain challenges highlighted in Table 1 have 
a negative impact on the availability and accessibility of medicine 
at the last mile. Moreover, another reason for supply chain inter-
ruptions could be the diverse geographical topographies ranging 
from plains to difficult-to-access mountainous areas. Public health 
chains can become more effective through interventions to im-
prove access to medicine focused on better availability, affordabili-
ty, quality and obtainability. The interventions will result in tools to 
increase healthcare coverage and achieve better health outcomes. 
They will also act as solutions to the various supply chain bottle-
necks that cannot be solved in isolation [18,19]. 
Improving the availability of medicine
It is discouraging to realise that an overwhelming majority of 
medicine is designed for the needs of high-income countries. This 
results from a lack of incentives for research and development of 
medicine for the needs of LMICs. Pharmaceutical companies op-
erate in a system influenced by the profits, where the consumers 
‘choose’ from the portfolio of drugs produced through demand 
[20]. However, the purchasing power is very low or non-existent 
in LMICs. Again, lack of funds results in high out-of-pocket expen-
diture that represents a similarly high proportion of the popula-
tion’s income. The lack of health insurances aggravates the issue 
further. Another trend that affects the availability of medicine is the 
inequality in research and development of medicine. Pharmaceuti-
cal companies consider the needs of LMICs only when a specific 
disease pathway lead to them and forcing the stretch beyond low 
profit margins [21].
Some of the existing solutions embraced by countries to 
strengthen research and development to improve the availability 
of medicine are:
•	 Grants: Research grants are a common tool to boost research 
and innovation into this problem. Applications are usually 
initiated by international donors and agencies. The grants 
help to cover the initial costs, and they are a step towards im-
proving health outcomes. Yet, such grants create dependency 
on the donors and their availability can be sporadic.
•	 Treaties: The implementation of a global research and devel-
opment (R&D) treaty was recommended by the WHO Consul-
tative Expert Working Group (CEWG) on Research and Devel-
opment: Financing and Coordination. The treaty is supported 
by over 80 health research institutions, product development 
partnerships, and public interest NGOs [22]. These treaties 
are crucial for the growth of LMICs [23].
•	 Market-based commitments: Advance market commit-
ments create an agreement in advance of the development of 
a product to purchase guaranteed amounts that meet criteria 
set by the donor (Commission on Intellectual Property Rights, 
Innovation and Public Health, 2006). Critics have opined that 
it is difficult to measure the success of these strategies be-
cause of the complexity and time involved [24].
•	 Priority Review Vouchers: These provide incentives for re-
search and development by shortening the review process of 
future medicine. However, investigation shows that these are 
not used widely [25].
•	 Product Development Partnerships: These are initiatives 
to bring together public, private and funding organisations to 
provide an impetus for improving the availability of medicine 
through research and development [25]. This is an opportu-
nity for developing nations to combine the efforts of the vari-
ous stakeholders and work towards better health coverage. 
These partnerships try to strike a balance between public and 
private interests [26].
•	 Patent Pools: These involve the cross-licensing of intellectual 
property by participants to increase access to essential tech-
nologies for products [26]. These pools act as a uniform plat-
form for licensing of all patents and make the process of drug 
discovery more efficient. However, it should be noted that use 
of patent pools for pharmaceutical R&D is relatively new, and 
they have not been widely used [27].
However, the above-mentioned initiatives have not yielded 
many results in LMICs. Therefore, some of the interventions that 
can be adopted are
•	 Tradable patent terms can be introduced, meaning that phar-
maceutical initiatives serving a humanitarian purpose would 
receive an extended patent term that can be used with a dif-
ferent pharmaceutical product [28].
•	 Pharmaceutical companies are urged to begin systemati-
cally planning ahead during clinical development to ensure 
that successful products can be made widely available more 
quickly in developing countries. They can pioneer voluntary 
licensing and establish multi-sector capacity development 
partnerships [29].
•	 Refocusing the direction of the major stakeholders may be 
needed to boost meaningful research and development in 
LMICs. Pharmaceutical companies need to take more respon-
sibility, allocate time and resources to improve healthcare in 
LMICs [30]. Priorities must span across diseases, conditions 
and pathogens and the different products needed per disease, 
such as medicine or diagnostic tools.
•	 State-run programmes can ease off the pressure from private 
sector. This will also induce accountability into the public sec-
tor for the availability of medicine.
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The affordability of medicine is the ability of the population to 
pay for medicine without compromising other essentials, such as 
housing, education and food. Affordability also depends on who is 
paying–the patient or another stakeholder in the local healthcare 
system. In LMICs nearly 70% of spending on medicine is out-of-
pocket. Different countries have different income capacities and 
these differences should be kept in mind while deciding the prices 
of medicine. The cost of medicine is usually determined by the 
cost of manufacturing, supplying, and the research involved. The 
costs often do not include the opportunity cost and are inflated to 
reap higher profits. Studies have highlighted that efforts to make 
medicine more affordable are lacking in LMICs by comparison to 
developed countries [31], mainly due to lack of funding [32]. LMICs 
do not have efficient systems for clinical trials, top-level medical 
schools and experienced clinicians [33] which hinders access to af-
fordable medicine (IFPMA). Again, affordability of medicine is in-
fluenced by huge mark-ups resulting in poor healthcare coverage. 
Improving the quality of medicine
Improving the affordability of medicine
•	 Differential pricing can be adopted allowing LMICs to pay for 
medicine based on their ability and per capita household in-
come.
Some of the existing tools embraced by countries to improve af-
fordability by reducing the cost of medicine are:
•	 Differential pricing, which occurs when varying prices are 
charged by the seller according to the purchasing power of 
governments and households in different countries [34]. 
However, it involves a high risk of arbitrage and erosion of 
high-income markets [35].
•	 Monopsonies are market structures where the buyer has the 
control power. In many countries, when public procurement 
is done by the government, it functions as a monopsony, al-
lowing for the negotiation of lower prices (e.g.: PHARMAC in 
New Zealand). This kind of a market structure can help to re-
duce the cost of the medicine, generating better savings and 
allowing affordable health treatment. On the other hand, this 
model can suffer from lack of transparency and knowledge, 
since most contracts are confidential [36].
•	 Patent law flexibilities can include changing the terms of pat-
ents, strengthening patent criteria and introducing competi-
tion [37].
Inferior quality medication and counterfeit products have a 
negative impact on the health systems of any country, especially of 
LMICs, where some disease reports indicate that half of the drugs 
may have few to no active ingredients [40]. Medicine may also con-
tain toxic substances which are harmful for the community. These 
issues can cause treatment failure, extended illness, adverse reac-
tions, disability and death [41]. Substandard medicine often looks 
very similar to the original and it is difficult to differentiate them. 
The lucrative nature of these products often fosters cross-border 
criminal activities, making detection and prosecution difficult. The 
counterfeits attract the various stakeholders alike and lack of prop-
er legislation, enforcement and heavy penalties make deterrence 
very limited [42]. Detection is also made difficult by the spread of 
supply chains across different countries and continents, meaning 
that they are not unified in a single system [43]. Another factor that 
impacts on the quality of medicine is that legally produced gener-
ics legally produced may confiscated (en route) on grounds of IP 
breach even, though the destination country could legally distrib-
ute it [44].
As with availability, the previous initiatives have not yielded vis-
ible results in LMICs. Therefore, some of the interventions that can 
be adopted to improve affordability of medicine could be:
•	 Increased transparency between the pharmaceutical sector 
and the country government to understand contexualised 
needs and challenges. Pharmaceutical companies can work 
with national governments and partners to expand pricing 
schemes and donation programmes.
•	 LMICs must have the political will to increase affordability, 
and the capacity and financing to develop policy and effective 
systems to that effect.
•	 Backdoor deals and evergreening need to be stopped com-
pletely. Backdoor deals occur when a monopolist incentivises 
a local company to stay away from the market [38]. Evergreen-
ing refers to penetration of secondary patenting of the most 
successful medicine, which may further reduce the ability of 
generics to enter the market [39].
•	 Time-bound targets for new products in LMICs will help to se-
cure market access and grow a strong market share.
•	 It is necessary to enforce obligations on pharmaceutical firms 
to ensure that life-saving medicine is provided in LMICs [30]. 
This can be achieved by prioritising research and develop-
ment on disease gaps.
•	 Socio-economic factors are to be frequently considered while 
setting medicine prices. The factors considered the most rel-
evant are disease burden, healthcare system and financing; 
and the level of economic and human development. This will 
help in creating patient access profiles and facilitate better af-
fordability. 
•	 Stakeholders should explore ways of mobilising new and in-
novative means of financing, developing and increasing re-
sources available for health.
Currently, the efficacy of medicine is generally checked, and the 
desired quality achieved through the following initiatives:
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• Product Authentication uses colour shifting inks, holograms  
 and chemical markers embedded in drugs to identify legiti 
 mate medicines [45].
• E-coding is another method followed by many countries to  
 help identify substandard drugs. For example, China uses an  
 ‘e-coding’ system whereby each party within the supply chain  
 is required to send a ‘signal’ to confirm receipt or dispatch to  
 a regulatory database [46].
• Track and trace devices and technology.
• National enforcement of strict sanctions and penalties.
These general measures have not yielded the results LMICs. 
Therefore, some of the interventions that can be adopted to im-
prove quality of medicine are:
•	 Educating patients and healthcare workers on the accurate 
identification and use of the medicine through means that 
meet a range of needs, including language, literacy and cul-
tural, demographic and environmental needs.
•	 Creation of international marking systems, so that medicine 
does not need to be re-marked when entering a new country, 
saving supply chain costs and lead times.
•	 Stakeholders should have policies, procedures and resources 
in place to carry out effective drug recalls to protect the pub-
lic from a defective or potentially harmful product.
•	 Sharing of information and communication by identifying 
emerging markets, particularly, when it comes to the imple-
mentation of segmented pricing and product registration fil-
ings, and to transferring knowledge, expertise and other ca-
pacities to the local manufacture of pharmaceutical products.
•	 Inclusion of LMICs in international frameworks.
•	 More research regarding substandard medicine is needed as 
the prevalence of substandard medicine is still the result of 
‘informed guesses’ [40].
•	 An international code of practice to aid in coordinating regu-
latory, customs and law enforcement agencies.
The existing initiatives to overcome these challenges are:
•	 Task-shifting is a tool embraced to develop the existing hu-
man capacity and provide a more sustainable solution. This 
process involves the movement of specific tasks from highly 
qualified workers to those with less training and fewer quali-
fications, in order to make more efficient use of the available 
human resources for health [49].
•	 Interventions through grassroots organisations (GROs), made 
up of interested parties coming together for self-help (as op-
posed to interested parties coming together to help others, as 
tends to happen in the sector) [48].
Once again, these initiatives have not yielded adequate results in 
LMICs. Some interventions that can be adopted to improve the ob-
tainability of medicine are:
•	 Acceptance and identification of supply chain issues which 
are resulting in poor rates of medicine obtainability at the 
last-mile. This can be achieved through capacity planning 
and development at the various levels. Initiatives in this area 
range from training on good distribution practice, proper 
warehousing, forecasting and cold chain requirements, to 
projects that use technology to track stock and prevent stock-
outs.
•	 Strong political will to support the public health systems and 
supply chains to overcome bottlenecks by creating more dis-
tribution hubs, even in rural areas. 
•	 Tailored mechanisms for change using contexualised and is-
sue-driven technology, avoiding the blind adoption of modern 
technology without recognition of grassroot realities.
•	 Aligning global, regional and country-level supply planning 
processes with demand for the products by making efforts to 
understand product distribution and demand behaviour in 
different countries and applying the information for timely 
supply. 
•	 The socio-economic determinants of health must be recog-
nised in order to define a holistic framework.Improving obtainability of medicine
In public health, the availability of medicine is considered a 
crucial issue. However, most of the studies overlook obtainability, 
since it is determined by a host of factors both within and outside 
the country’s control. Obtainability can be influenced by challenges 
in the country’s health system, infrastructure, legal barriers, socio-
cultural influences, etc. [47]. This leads to patient unawareness and 
adherence to non-standardised practice. Again, the availability of 
healthcare personnel per capita is very low in LMICs, reducing the 
possibility of preventative medicine and diagnosis. Doctors and 
other healthcare personnel may be concentrated in urban areas, 
leaving rural populations without easy access to basic healthcare. 
In rural areas, it may be very time-consuming or expensive to reach 
the nearest health point or distribution facility [48]. It is also ob-
served that the wholesale market is excessively fragmented with 
poor traceability [47]. Even, if the medicine makes it to the local 
community centre, access may be physically restricted due to lack 
of basic infrastructure.
Improving access to new medicine
It is critical for all LMICs to have access to new drugs and med-
icine. This can be done through proper advance planning on the 
part of the various stakeholders and through a clear understanding 
of the access plan. Pharmaceutical companies can voluntarily enter 
licensing agreements under pro-access terms to facilitate generic 
entry [50]. This can be achieved through planning for and aligning 
with other actors along supply chains to ensure the timely supply 
of good quality products and prevent stockouts. 
Planning can also be done through submitting products to 
WHO’s prequalification process to allow for UN procurement and 
accelerate the registration process in countries with weak national 
regulatory authorities [51]. Access plans can also be implemented 
through local partners to make the new products widely accessible. 
Generally, access plans first take the shape of commitments made 
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Matching the interventions to WHO building blocks and sup-
ply chain functions 
It is well-recognised that access to medicine is not only a mat-
ter of life and death; it also enhances the quality of life and it is 
important for overall improved standards of living. Access to medi-
cine is a complex and multi-dimensional issue calling for holistic 
solutions. Measures must include improving supply chains, under-
standing social determinants of health, encouraging policy coher-
ence, implementing proactive intellectual property regimes, and 
ensuring that health delivery systems are appropriate to those they 
•	 Analytical/Scientific: These interventions help in generating 
new ideas and foster innovations to improve access to medi-
cines.
•	 Structural: These interventions establish processes, proce-
dures, and platforms to enhance and facilitate activities. 
•	 Collaborative: These interventions enhance co-ordination 
among the various stakeholders and technical partners. 
•	 Legislative: These interventions aim to bring changes in the 
legislative frameworks and boost political will.
•	 Workforce development: These interventions facilitate 
building the capacity of the workforce.
Access to 




Tradable patent Analytical/Scientific Information and Research
Systematically planning during clinical develop-
ment
Structural Information and Research
Refocusing of the direction of the Major stake-
holders
Collaborative Leadership and Governance, Service 
delivery
State-run programmes Legislative Leadership and Governance, Service 
delivery




Increased transparency between the pharma-
ceutical sector and the country government
Collaborative and Legislative Leadership and Governance
Political will Legislative Leadership and Governance
Backdoor deals and evergreening need to be 
stopped
Collaborative and Legislative Leadership and Governance
Time-bound targets for filling to register new 
products
Analytical/Scientific Information and Research
Setting priority research and development ac-
count to focus on disease gaps.
Analytical/Scientific Information and Research
Mobilizing new and innovative means of financ-
ing
Structural Finance
Socio-economic factors Structural Leadership and Governance
Improving 
the quality of 
medicine
Educating patients and healthcare workers Workforce development Health Workforce
International marking systems Collaborative, legislative Leadership and governance
Effective drug recalls Structural Information and Research
Sharing of information and communication Collaborative Information and Research
International frameworks and code of practice Legislative Leadership and governance, Service 
delivery





Capacity planning and development Workforce development Health Workforce
Strong political will to support the public health 
systems and supply chains
Legislative, Structural Leadership and Governance, Service 
delivery
Tailored mechanisms for change Collaborative Leadership and governance
Aligning global, regional and country-level sup-
ply planning processes with demand
Structural
Service delivery, Information and Re-
search
Socio-economic determinants of health Structural Leadership and Research, Service de-
livery
during the early stages of development before being turned into 
concrete strategies or agreements. This is a necessary first step, 
and efforts must be made to ensure these commitments are turned 
into action.
serve. The following table summarises the proposed interventions 
and their areas of focus. We have identified the following areas of 
focus: 
Table 2: Proposed interventions and the area of focus in developing nations.
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We also link each intervention to a WHO Building Block (refer 
to Table 2) and the corresponding supply chain management func-
tions (refer to Table 3). This mapping will support stakeholders 
get a broader picture and envision policies, which will contribute 
towards comprehensive solutions to strengthen the public health 
supply chains in developing nations. Establishing better rational-
ity to decisions and building it on relevant constraints will support 
developing nations propel towards stronger health systems and 
public health supply chains.
WHO Building 
Block Supply chain functions
Information 
and Research




Policies, co-ordination, transparency,  
accountability, change management,  
stakeholder management




Staffing, skills, supervision, performance 




Procurement, warehousing, distribution tools, 
transportation, technology, last mile delivery
Table 3: WHO Building Blocks and supply chain functions.
Conclusion
Access to medicines requires efficient public supply chains 
where each component of the cycle is aligned with the performance 
of the other. If one component is not managed correctly, other com-
ponents are bound to be adversely impacted. With an efficient sys-
tem in place, procurement, and distribution of appropriate medi-
cine and equipment, rational diagnostic, therapeutic practices can 
be promoted in LMICs. The integration of strategies into contex-
tualised frameworks will create a sustainable roadmap for better 
access to medicine. Developing nations are the new frontiers for 
growth, and hence provide opportunities to improve the quality of 
human care and innovations. This creates a platform for the various 
stakeholders to enter, understand, and develop effective policies to 
have a more positive and significant effect on the majority of the 
population. Interventions to improve universal healthcare through 
better access to medicine will benefit LMICs with improved health 
systems and solutions to local needs. Since the disease patterns 
and the strength of public health systems differ across countries, 
tailored interventions which incorporate training for healthcare 
workers and health financing can help overcome country-specific 
barriers. Inclusive involvements will aim to include people living 
on very low incomes to improve access to specific medicine or 
other health products. This will make a tremendous difference and 
provide medicine which the poor people cannot afford and at the 
same time reduce the out-of-pocket expenditure.
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